Moderna Q3 EPS Raised by Brookline Capital Markets

by · The Markets Daily

Moderna, Inc. (NASDAQ:MRNA – Free Report) – Stock analysts at Brookline Capital Markets raised their Q3 2026 earnings per share estimates for Moderna in a report released on Monday, August 31st. Brookline Capital Markets analyst L. Cann now forecasts that the company will post earnings per share of ($1.24) for the quarter, up from their previous forecast of ($1.30). Brookline Capital Markets has a “Buy” rating on the stock. The consensus estimate for Moderna’s current full-year earnings is ($6.11) per share. Brookline Capital Markets also issued estimates for Moderna’s Q4 2026 earnings at ($2.09) EPS, FY2026 earnings at ($6.46) EPS, FY2027 earnings at ($3.13) EPS and FY2028 earnings at $0.62 EPS.

Several other brokerages have also issued reports on MRNA. Loop Capital set a $135.00 target price on Moderna in a report on Wednesday, August 19th. CLSA raised Moderna to an “outperform” rating in a research note on Friday. JPMorgan Chase & Co. raised their price objective on Moderna from $40.00 to $77.00 and gave the stock an “underweight” rating in a research report on Friday, August 21st. Citigroup lifted their price objective on Moderna from $41.00 to $60.00 and gave the stock a “neutral” rating in a research note on Monday, August 3rd. Finally, The Goldman Sachs Group increased their target price on shares of Moderna from $67.00 to $120.00 and gave the company a “neutral” rating in a research report on Wednesday, August 19th. Seven investment analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $80.53.

Read Our Latest Analysis on Moderna

Moderna Trading Up 9.9%

Shares of Moderna stock opened at $154.27 on Wednesday. The firm’s 50 day moving average is $80.59 and its 200 day moving average is $61.34. The firm has a market capitalization of $61.59 billion, a PE ratio of -19.31 and a beta of 1.09. Moderna has a 1 year low of $22.28 and a 1 year high of $176.66. The company has a current ratio of 2.29, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09.

Moderna (NASDAQ:MRNA – Get Free Report) last issued its earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, topping the consensus estimate of ($2.03) by $0.06. The firm had revenue of $145.00 million during the quarter, compared to the consensus estimate of $102.93 million. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.The business’s quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($2.13) earnings per share.

Insider Activity

In other news, President Stephen Hoge sold 53,336 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $51.37, for a total value of $2,739,870.32. Following the transaction, the president directly owned 1,483,848 shares of the company’s stock, valued at $76,225,271.76. The trade was a 3.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Thyme Klinger sold 3,471 shares of the business’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $50.00, for a total value of $173,550.00. Following the completion of the transaction, the insider directly owned 67,468 shares in the company, valued at $3,373,400. This represents a 4.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 10.80% of the company’s stock.

Hedge Funds Weigh In On Moderna

A number of institutional investors and hedge funds have recently modified their holdings of MRNA. BlackRock Inc. bought a new stake in shares of Moderna in the 2nd quarter valued at $2,142,877,000. California State Teachers Retirement System lifted its position in shares of Moderna by 6,698.1% during the 2nd quarter. California State Teachers Retirement System now owns 27,681,318 shares of the company’s stock valued at $1,938,523,000 after acquiring an additional 27,274,128 shares during the period. Capital World Investors bought a new position in Moderna during the fourth quarter worth $378,299,000. Theleme Partners LLP acquired a new stake in Moderna in the second quarter worth $564,272,000. Finally, Alyeska Investment Group L.P. acquired a new stake in Moderna in the fourth quarter worth $95,209,000. 75.33% of the stock is currently owned by institutional investors.

Trending Headlines about Moderna

Here are the key news stories impacting Moderna this week:

  • Positive Sentiment: Brookline raises near- and medium-term forecasts: Brookline Capital Markets maintained a “Buy” rating and raised its EPS estimates for Q3 2026 to ($1.24) from ($1.30), Q4 2026 to ($2.09) from ($2.16), FY2026 to ($6.46) from ($6.60), FY2027 to ($3.13) from ($3.24), and FY2028 to $0.62 from $0.53. The revisions suggest the analyst sees a somewhat faster path toward profitability, despite Moderna still being expected to report losses in 2026 and 2027. MarketBeat Moderna analyst estimates
  • Positive Sentiment: Promising oncology results remain the key catalyst: Moderna and Merck reported positive late-stage results for their personalized melanoma vaccine, reinforcing the potential for Moderna to expand beyond COVID-19 vaccines and build a higher-value oncology business. Moderna oncology catalyst
  • Positive Sentiment: Investor interest remains elevated: Options activity was unusually strong, with traders purchasing 106,605 call options—about 35% above typical call volume. This signals bullish positioning, although options activity can also increase volatility.
  • Neutral Sentiment: Moderna will present at the Morgan Stanley Global Healthcare Conference on September 14 and the Bernstein Healthcare Forum on September 23, giving investors opportunities to hear updates on its pipeline, commercial outlook and financial plans. Moderna conference schedule
  • Negative Sentiment: Competition in mRNA influenza vaccines is increasing: GSK advanced its rival mRNA flu vaccine into Phase III, creating a future competitive threat. However, Moderna’s recent FDA approval for the first seasonal mRNA flu vaccine means investors appear to view the development as validation of the market rather than an immediate commercial setback. GSK mRNA flu vaccine Phase III
  • Negative Sentiment: Brookline modestly reduced its long-range EPS forecasts for FY2029 to $11.54 from $11.69 and FY2030 to $19.11 from $19.27. The cuts are small, but they temper the otherwise improving near-term outlook.

Moderna Company Profile

(Get Free Report)

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.

Featured Articles